Summary
Health Catalyst reported third-quarter 2020 total revenue of $47.2 million, up 19.7% from the prior-year quarter. New DOS subscription customers, recent acquisitions, and contractual annual escalators on technology access fees drove the increase. The net loss was $27.3 million, wider than $21.4 million in the prior-year quarter. The operating loss was $23.5 million, wider than the $20.7 million operating loss a year earlier. Diluted EPS was -$0.68. Operating margin was -49.7%, up from -52.6% in the prior-year quarter.
Non-GAAP measures show a smaller loss. Adjusted EBITDA was negative $6.4 million, compared with negative $8.4 million in the prior-year quarter. Total adjusted gross margin slipped to 51% from 54%. Adjusted technology gross margin held at 68%, while adjusted professional services gross margin fell to 25% from 37%. Management tied that drop to lower professional services dollar-based retention, temporary discounts given to customers under financial strain from COVID-19, and a shift in the mix of services delivered. Adjusted net loss was $8.3 million, compared with $9.8 million, and pro forma adjusted net loss per share was $0.21, compared with $0.27. Remaining performance obligations were $85.8 million, up 34.1% from the prior-year quarter. Deferred revenue was $36.7 million, down 7.3%.
COVID-19 remains the main swing factor. The company says more than 90% of revenue is recurring and that customer use of its data platform has never been higher, with demand shifting from pandemic preparedness toward financial recovery and planning analytics. Even so, health system financial strain cut professional services dollar-based retention, and net new DOS subscription customer additions through the first nine months ran below the plan entering the year. Health Catalyst also closed the Able Health, Healthfinch, and Vitalware acquisitions, and it is migrating customers off on-premise and managed data centers to Microsoft Azure. The Azure move lifts cost of technology revenue and is a near-term headwind to adjusted technology gross margin.
Cash flow and the nine-month picture were weaker than the headline growth. Operating cash flow was negative $4.5 million for the quarter, up from negative $5.5 million in the prior-year quarter. For the first nine months of 2020, operating cash flow was negative $22.0 million, down 15.1% from negative $19.1 million in the same period of 2019. Capital expenditures were $1.0 million in the quarter, up 68.7% from $0.6 million in the prior-year quarter. Nine-month revenue was $135.6 million, up 21.6% from $111.4 million. The nine-month net loss was $72.0 million, and the nine-month operating loss was $57.2 million. Nine-month adjusted EBITDA was negative $16.6 million, compared with negative $20.9 million.
Guidance points to a wider loss in the fourth quarter. For the fourth quarter of 2020, the company guided Adjusted EBITDA between negative $7.3 million and negative $5.3 million, and it also issued total revenue guidance for the quarter. For the full year 2020, it guided Adjusted EBITDA between negative $23.9 million and negative $21.9 million, alongside total revenue guidance for the year. The release did not reconcile forward-looking Adjusted EBITDA to net loss because items such as stock-based compensation fall outside management's control or cannot be reasonably predicted. Risks flagged in the filing include COVID-19 disruption to customers and sales cycles, the loss of key customers or partners, litigation or a security incident, regulatory changes, and difficulty recruiting and retaining qualified team members. Health Catalyst also announced leadership changes effective January 1, 2021. Patrick Nelli moves from CFO to President, Bryan Hunt becomes CFO, Jason Alger becomes Chief Accounting Officer, and Adam Brown adds financial planning and analysis to his investor relations role.
Forecast
Reported figures
GAAP, from SEC filings| Metric | Q3 FY2020 | Q2 FY2020 | QoQ | Q3 FY2019 | YoY |
|---|---|---|---|---|---|
| Revenue | $47.2M | $43.3M | +9.1% | $39.4M | +19.7% |
| Research & development | $13.4M | $12.1M | +11.0% | $13.5M | -0.6% |
| Sales & marketing | $14.6M | $12.5M | +17.0% | $14.7M | -0.6% |
| General & administrative | $13.3M | $8.1M | +63.9% | $11.0M | +20.7% |
| Total operating expenses | $46.3M | $35.8M | +29.4% | $41.5M | +11.5% |
| Operating income (loss) | -$23.5M | -$15.6M | -50.0% | -$20.7M | -13.1% |
| Operating margin | -49.7% | -36.1% | -13.6 pp | -52.6% | +2.9 pp |
| Net income (loss) | -$27.3M | -$27.2M | -0.5% | -$21.4M | -27.6% |
| Net margin | -57.9% | -62.8% | +4.9 pp | -54.3% | -3.6 pp |
Risks
COVID-19 has disrupted healthcare provider customers, causing lower year-to-date professional services dollar-based retention, temporary professional services discounts, and lower net new DOS subscription customer additions than planned. Adjusted Professional Services Gross Margin decreased from 37% for the three months ended September 30, 2019 to 25% for the three months ended September 30, 2020.
Sales cycle for a new customer has averaged 11 months and in some cases exceeded 24 months. COVID-19 procurement distraction and long procurement cycles contributed to lower year-to-date net new DOS subscription customer additions, and any further lengthening could delay revenue relative to operating expenses.
The company has acquired Medicity in June 2018, Able Health in February 2020, Healthfinch in July 2020, and Vitalware in September 2020, creating integration and cross-sell risk. Medicity customers have generated a lower Dollar-based Retention Rate and are expected to have flat to declining revenue in the foreseeable future.
Most subscription contracts are terminable after one year upon 90 days notice, and customers may fail to renew or renew at lower fee levels. Deferred revenue decreased 7.3% year over year to $36.7 million at September 30, 2020, and lower professional services dollar-based retention was driven by COVID-19.
Intense competition from EHR companies such as Epic Systems and Cerner and from large entities such as Optum Analytics and IBM, with increased competition likely to result in pricing pressures. Changes in healthcare industry and customer or vendor consolidation could also cause existing customers to terminate contracts or demand unfavorable terms.
The transition of customers from on-premise and managed data centers to Microsoft Azure is more costly per customer, will result in higher cost of technology revenue, and provides a headwind against increases in Adjusted Technology Gross Margin. The Solution also depends on third-party providers including Microsoft Azure for computing infrastructure, and any disruption could adversely affect business.
Several senior leaders are active members of the Church of Jesus Christ of Latter-Day Saints and may receive a call to serve in a full-time capacity. Co-founder Steven Barlow was called to serve from June 2017 to June 2020 and returned in August 2020, highlighting the risk that key executives could depart.
Changes in healthcare regulation, customer and vendor consolidation, and reductions in healthcare expenditures could reduce demand, terminate existing contracts, or make new contracts harder to negotiate. Failure by customers to obtain proper permissions and waivers may result in claims or limit or prevent use of data.
If the Solution fails to provide accurate and timely information or is associated with faulty clinical decisions or treatment, the company could face liability to customers, members, clinicians, or patients. Contractual liability limits and insurance may not fully protect against large claims.
The Solution depends on the ability to source data from third parties, and such third parties could block access to data or fail to provide it, which could impair the Solution or limit its effectiveness.
The April 2020 issuance of $230.0 million of 2.50% Convertible Senior Notes due 2025 and related Capped Calls expose the company to counterparty default risk on the option counterparties. Interest expense increased $4.9 million for the nine months ended September 30, 2020 due to net borrowings from the Notes Offering.
Historically, the company has relied on a limited number of customers for a significant portion of revenue and accounts receivable; the three largest customers comprised 11.8% of 2019 revenue and 17.5% of 2018 revenue. Loss, termination, or renegotiation of any largest customer contract could negatively impact results.
On the last business day of the second quarter of fiscal 2020, non-affiliate market value exceeded $700 million, so as of December 31, 2020 the company will be a large accelerated filer and cease to be an emerging growth company, losing the exemption from Section 404(b) auditor attestation. If internal controls have material weaknesses, investors may lose confidence in financial reports.
SaaS KPIs
All quarters →Adjusted EBITDA
Recurring revenue
Summary, forecast, risks and KPIs are extracted from Health Catalyst, Inc.'s SEC filings for Q3 FY2020 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 21, 2026.